1430061-61-2

Basic information

• Product Name: benzyl (4S,7S)-4-(2-(4-bromophenyl)-2-oxoethylcarbamoyl)-6,10-dioxooctahydro-1H-pyridazino[1,2-a][1,2]diazepin-7-ylcarbamate
• Synonyms: benzyl (4S,7S)-4-(2-(4-bromophenyl)-2-oxoethylcarbamoyl)-6,10-dioxooctahydro-1H-pyridazino[1,2-a][1,2]diazepin-7-ylcarbamate
• CAS NO: 1430061-61-2
• Molecular Weight: 571.428
• Mol File: 1430061-61-2.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: benzyl (4S,7S)-4-(2-(4-bromophenyl)-2-oxoethylcarbamoyl)-6,10-dioxooctahydro-1H-pyridazino[1,2-a][1,2]diazepin-7-ylcarbamate(CAS DataBase Reference)
• NIST Chemistry Reference: benzyl (4S,7S)-4-(2-(4-bromophenyl)-2-oxoethylcarbamoyl)-6,10-dioxooctahydro-1H-pyridazino[1,2-a][1,2]diazepin-7-ylcarbamate(1430061-61-2)
• EPA Substance Registry System: benzyl (4S,7S)-4-(2-(4-bromophenyl)-2-oxoethylcarbamoyl)-6,10-dioxooctahydro-1H-pyridazino[1,2-a][1,2]diazepin-7-ylcarbamate(1430061-61-2)

Safety Data

• Hazardous Substances Data: 1430061-61-2(Hazardous Substances Data)

Upstream product

• 106928-72-7 (1S,9S)-t-butyl 1,2,3,4,7,8,9,10-octahydro-6,10-dioxo-9-phthalimidopyridazino<1,2-a><1,2>diazepine-1-carboxylate 
• 174799-32-7 (1S,9S)-9-(benzyloxycarbonylamino)-6,10-dioxooctahydro-1H-pyridazino[1,2-a][1,2]diazepine-1-carboxylic acid 
• 5467-72-1 α-amino-4-bromoacetophenone hydrochloride 
• 88767-96-8 (1S,9S)-t-butyl 9-amino-octahydro-6,10-dioxo-6H-pyridazino<1,2-a><1,2>diazepine-1-carboxylate 
• 174799-31-6 (1S,9S)-tert-butyl 9-(benzyloxycarbonylamino)-6,10-dioxooctahydro-1H-pyridazino[1,2-a][1,2]diazepine-1-carboxylate 

Downstream Products

• 1430061-51-0 {(4S,7S)-4-[5-(4'-{2-[(S)-1-((S)-2-methoxycarbonylamino-3-methylbutyryl)pyrrolidin-2-yl]-3H-imidazol-4-yl}biphenyl-4-yl)-1H-imidazol-2-yl]-6,10-dioxooctahydropyridazino[1,2-a][1,2]diazepin-7-yl}carbamic acid benzyl ester 
• 1430061-52-1 benzyl (4S,7S)-4-(5-(4-bromophenyl)-1H-imidazol-2-yl)-6,10-dioxooctahydro-1H-pyridazino[1,2-a][1,2]diazepin-7-ylcarbamate 

Relevant articles and documents

ANTIVIRAL COMPOUNDS

The present invention discloses compounds of Formulae I and II, wherein the variables in Formulae I and II are defined as described herein. Also disclosed are pharmaceutical compositions containing such compounds and methods for using the compounds of Formulae I and II in the treatment of HCV infection.